Test
Clinical Utility
This advanced test evaluates risk factors for cardiovascular disease (CVD) plus metabolic factors associated with metabolic syndrome and type II diabetes. In addition to the traditional CVD risk factors, the test includes much more clinically sensitive atherogenic lipoprotein sub-species, the primary apolipoproteins, arterial inflammation and the activity of the lipoprotein- associated phospholipase- A2 (PLAC). PLAC activity is a very sensitive indicator of active atherogenesis and instability of advanced arterial plaque. Metabolic syndrome (MetS) is centered around insulin resistance and atherogenic dyslipoproteinemia, and is a risk factor associated with CVD and kidney disease. The test includes cystatin C to better assess glomerular filtration, and 1,5-anhydroglucitol (Glycomark) that is a better indicator of hyperglycemic episodes than HbA1C. The primary adipokines associated with insulin sensitivity and hepatic fatty acid metabolism are also addressed
Source: https://www.doctorsdata.com/cardiometabolic-profile-serum/;Accessed 23-May-2019
Result Included
- Adiponectin
- Apolipoprotein, A1
- Apolipoprotein
- C-Reactive Protein
- Cholesterol
- Creatinine
- Cystatin C
- Glucose
- Glycomark (1,5-AG)
- HDL
- Homocysteine
- Insulin
- LDL
- Leptin
- Adiponectin ratio
- Leptin
- Lipoprotein (a)
- Oxidized LDL
- PLAC (LP-PLA2 Activity)
- Triglycerides
- small dense LDL
Test Location
Doctor's Data
Specimen
Specimen Type
SerumCollection & Handling
Additional Information
A specimen collection kit is available. To order a kit online, please register or login. For assistance or more information, please click here to send us an email or call 416-422-3000 x 300.
For additional information refer to the Doctors Data websiteCardiometabolic Profile
Rejection Criteria
| Criteria | Specification |
|---|---|
| Hemolysis | Present |
Sample Report
Turnaround Time
7 Days
Sample Report
Sample Report at external website.
Test Version
Last Updated
2022-05-09